Nordic Nanovector Announces that the data from the LYMRIT 37-05 Phase 1 Trial of Betalutin in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) will be presented at EHA 2022 Meeting

OSLO, Norway, June 10, 2022 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANOV) announces an update from the LYMRIT 37-05 Phase 1 trial investigating Betalutin (177Lu lilotomab satetraxetan)

Related Keywords

Norway ,Japan ,Austria ,Vienna ,Wien ,Gomez Codina ,Erik Skullerud ,Malene Brondberg ,Frazer Hall Medi ,European Hematology Association ,Nordic Nanovector ,Abstract Code ,Stem Cell Transplantation ,South Asian ,Disease Landscape ,Frazer Hall ,Securities Trading ,Nordic ,Nanovector ,Nnounces ,Data ,Rom ,Ymrit ,Hase ,Trial ,Etalutin ,Relapsed ,Refractory ,Diffuse ,Barge ,Fell ,Lymphoma ,Dlbcl ,Resented ,022 ,Meeting ,